Abstract
827 Background: Capecitabine is a 5 flouropyrimidine derivative that is an orally administered, tumor activated and tumor selective agent. The drug has shown an excellent response in anthracycline and taxane refractory metastatic breast cancer patients (pts). Methods: Pts of advanced breast cancer were treated with capecitabine alone or in combination with other agents.The response rate, toxicity, and time to tumor progression (TTP) was evaluated. Results: : 23 pts (between jan'2000 to march'03) with metastatic breast cancer were treated with capecitabine. The mean age was 55 years. All except one patients had received prior chemotherapy either as adjuvant and or for metastatic disease. Mean number of prior chemotherapy regimens received were two. 5-flurouracil was part of prior chemotherapy in ten patients. Mean number of metastatic sites were two. Only six patients had single site of metastasis. Site of metsastasis was lungs in 12, liver in 10, bones in 12, skin in 5. Sixteen patients received capecitab...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
